Lv1
28 积分 2026-03-27 加入
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial
1个月前
已完结
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
299MO DESTINY-Breast06 (DB-06) post-hoc analysis by physician’s choice of chemotherapy (TPC): Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs TPC in hormone receptor–positive (HR+), HER2-low or -ultralow metastatic breast cancer (mBC)
1个月前
已完结
299MO DESTINY-Breast06 (DB-06) post-hoc analysis by physician’s choice of chemotherapy (TPC): Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs TPC in hormone receptor–positive (HR+), HER2-low or -ultralow metastatic breast cancer (mBC)
1个月前
已完结
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
1个月前
已完结
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
2个月前
已完结
Detecting and Managing T-DXd–Related Interstitial Lung Disease: The Five “S” Rules
3个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
3个月前
已完结
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer
3个月前
已完结
Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ ERBB2 -Negative Early Breast Cancer
3个月前
已完结
皖公网安备34019202002308
